Oncolytics Biotech Inc.
ONCYHealthcare|Biotechnology|US
$0.44
-0.01 (-2.09%)
DCF Value
$0.02
Cash / Share
$0.03
About
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
Stock Price
-56.5%(1Y)
1M
-19.3%
3M
-45.2%
6M
-50.6%
YTD
-49.7%
1Y
-58.9%
3Y
-72.0%
5Y
-78.9%
Pipeline Summary
23 total trials8
Phase 1
14
Phase 2
1
Phase 3
0
Phase 4
Completed: 16Withdrawn: 1Active: 3Unknown: 1Recruiting: 1Terminated: 1
Active Trials (4)
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study
NCT04215146Breast Cancer Metastatic
Phase 2Active
Enrollment: 48 participants
INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study
NCT04445844Anatomic Stage IV Breast Cancer AJCC v8
Phase 2Active
Enrollment: 25 participants
A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab
NCT07280377Anal Cancer Metastatic
Phase 1Phase 2Active
Enrollment: 122 participants
FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer
NCT07446322Ras-mutated Metastatic Colorectal Cancer
Phase 2Recruiting
Enrollment: 60 participants
Key Facts
Market Cap$44.1M
Employees29
CEOJared Kelly
IPO DateOct 5, 2001
Beta1.24
52-Week Range$0.38 – $1.3
Avg Volume1,167,348
ExchangeNASDAQ
Websiteoncolyticsbiotech.com
Ownership
Float116.5%
Shares Outstanding100.4M
Recent Insider Trades
McAdory John BeardenOTHER
Jun 1, 2026500,000 shares @ $0.97
Glover Stephen C.OTHER
Jun 1, 20260 shares
Parsons James T.BUY
Mar 11, 202610,000 shares @ $1.03
Kelly JaredBUY
Mar 12, 20265,050 shares @ $0.96
Kelly JaredBUY
Feb 12, 202629,500 shares @ $0.84
Peers
Recent News
Translational Data from Anal Cancer Patients Show Pelareorep Drives HPV-Specific Immune Responses, Supporting its Potential Across HPV-Driven Cancers
Nov 4, 2026 · globenewswire.com
Oncolytics Biotech® Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven Cancers
Oct 27, 2026 · globenewswire.com
Oncolytics Biotech® to Present REO 033 Trial in Progress Abstract at ESMO Showcasing Pelareorep's Potential in Colorectal Cancer
Oct 20, 2026 · globenewswire.com
Oncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment
Oct 14, 2026 · globenewswire.com
Oncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update
Oct 12, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:26 AM